Buzz Stocks: Nike, Orexigen Therapeutics, and Xerox

Today's stocks to watch in the news include NKE, OREX, and XRX

Dec 19, 2014 at 9:17 AM
facebook X logo linkedin


U.S. equities are poised to end the week on a high note, with futures pointed sharply higher in pre-market trading. In company news, today's stocks to watch include athletic apparel titan Nike Inc (NYSE:NKE), drugmaker Orexigen Therapeutics, Inc. (NASDAQ:OREX), and business support company Xerox Corp (NYSE:XRX).

  • NKE is sitting 1.5% lower ahead of the bell, despite reporting better-than-expected quarterly profit and revenue figures. Overshadowing the solid results are disappointing global future orders, particularly in Japan and emerging markets. Taking a step back, Nike Inc has had a solid 2014, gaining 23.4% as of last night's close at $97.08, and recently bounced off its 50-day moving average. Nonetheless, the brokerage crowd is fairly divided on the shares, with 12 sporting "buy" opinions, compared to nine "holds." What's more, NKE's consensus 12-month price target of $101.56 is less than 5% from its current perch.

  • OREX's diet pill, known in the U.S. as Contrave, has been recommended for approval in Europe by the European Medicines Agency (EMA). As a result, the shares are pointed nearly 9% higher ahead of the open. Longer term, Orexigen Therapeutics, Inc. has advanced almost 17% year-over-year to trade at $6.29. Should the stock continue to rally, short sellers may be forced to cover their bearish positions. Roughly 32% of OREX's float is sold short, which would take more than three weeks to cover, at the equity's typical daily trading volume.

  • Finally, XRX is up 1.2% in electronic trading, after the company agreed to sell its IT outsourcing unit to France-based Atos. The deal is worth just over $1 billion, and is expected to close in the first half of 2015. On the charts, Xerox Corp has tacked on approximately 18% since this time last year to rest at $13.89, ushered higher by its 40-week moving average. Still, analysts are skeptical of the shares, with more than half of the covering brokerage firms doling out "hold" or worse ratings. What's more, XRX's consensus 12-month price target sits at $13.77, a discount to last night's close. Should the stock maintain its upward momentum, it could benefit from upgrades and/or price-target hikes.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI